Endometrial Cancer and Obesity: An Exercise and Diet Intervention for Weight Loss
I. To determine if participation in a 16-week exercise and diet intervention would elicit
weight loss, assessed by a 10% decrease in fat mass, in endometrial cancer (EC) patients.
I. To determine if participation in a 16-week exercise and diet intervention would improve
cardiorespiratory fitness (CRF) and muscular strength.
I. To determine if participation in a 16-week exercise and diet intervention could improve
quality of life (QOL), fatigue, and depression.
II. To determine the effects of a 16-week exercise and diet intervention on cardiovascular
Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients
also undergo multi-lifestyle interventions based on the dietary approaches to stop
hypertension (DASH) diet once weekly over 1 hour for up to 16 weeks.
After completion of study, patients are followed up for 16 weeks.
After completion of study, patients are followed up for 16 weeks.
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
I. To determine if women who are disease-free after successfully completing primary and
potential consolidation/maintenance, therapy for stage II-IV ovarian, fallopian tube or
primary peritoneal cancer and who are randomized to a healthy lifestyle intervention, will
have significantly increased progression-free survival compared to similar women who are
randomized to a usual care comparison group.
I. To determine if women who are randomized to the study intervention will have improved
general quality of life as measured by the General Health subscale of Research and
Development (RAND) 36-Item Health Survey (RAND-36).
II. To determine if women who are randomized to the study intervention will have improved
physical and bowel functioning as measured by the Physical Functioning subscale of RAND-36
and the Gastrointestinal Symptom Rating Scale (GSRS)-Irritable Bowel Syndrome (IBS), compared
to women who are randomized to usual care.
I. To assess patient compliance with the healthy lifestyle intervention by analyzing
biomarkers (e.g., total carotenoid) at baseline, 6, 12, and 24 months.
II. To explore the relationship between carotenoid exposure and progression free survival
from ovarian cancer.
III. To examine patient compliance with the healthy lifestyle intervention and to assess
which types of patients are more likely to be compliant with the healthy lifestyle
intervention and whether progression-free survival is better among compliant individuals.
IV. To explore the impact of the intervention on other aspects of quality of life such as
pain, role limitations due to physical health and emotional problems, mental health,
vitality, and social functioning as measured by the corresponding subscales of the RAND-36.
V. To explore the impact of the intervention on bowel functioning as measured with the
VI. To assess the association between subjectively measured sleep duration/quality (using the
Pittsburgh Sleep Quality Scale), anthropometric measurements, and self-reported dietary
energy intake among women previously treated for stage II-IV ovarian or primary peritoneal
VII. To assess and compare telomere length and rate of telomere shortening between ovarian
cancer survivors randomized to lifestyle intervention versus standard of care.
VIII. To assess effects of the intervention on biomarkers of metabolic health as measured by
changes in circulating insulin and related insulin resistance, lipids and inflammation.
IX. To determine if the intervention effect on the biomarkers listed above is modified by
baseline central adiposity.
X. To determine if the intervention effect on biomarkers listed above is mediated by change
in central adiposity.
XI. To evaluate changes in central adiposity using computerized tomography (CT) scan data
from regularly scheduled, routine surveillance CT scans to determine if change in CT-specific
visceral adiposity is associated with changes in biomarkers of metabolic deregulation and
inflammation in a random subsample.
OUTLINE: Participants are randomized to 1 of 2 groups.
GROUP 1 (LIFESTYLE INTERVENTION): Participants receive a dietary intervention designed to
promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of
micronutrient intake. Participants also undergo a physical activity intervention comprising a
moderately low aerobic regimen to raise the usual activity level. Participants also undergo
face-to-face counseling, receive educational materials and counseling focused on how to read
food labels to estimate grams of fat per serving and serving size, and undergo telephone
counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2
weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every
other month for 12 months. Participants complete daily fat gram and step diaries at least
three times per week.
GROUP 2 (COMPARISON LIFESTYLE): Participants receive a study notebook containing general
study-related information. Participants are not asked to record diet or physical activity but
are provided a single sample diary in their study notebook. Participants receive telephone
contact on a sliding scale similar to the intervention group, but at less frequent intervals
(22 versus 33 calls over the course of the intervention).
After completion of study, participants are followed up every 3 months for 2 years, every 6
months for 3 years, and then annually thereafter.
A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy
I. To obtain preliminary estimates of the impact of a restricted diet on toxicity and
efficacy of chemotherapy for breast and prostate cancer.
II. To evaluate the compliance with a controlled diet intervention.
III. To investigate changes in plasma insulin, glucose, insulin-like growth factor 1 (IGF1)
and IGF binding protein (IGFBP) levels in subjects who consume a restricted diet compared to
Patients are randomized to 1 or 2 treatment arms.
ARM I: Patients eat a special low-calorie diet during 3 days prior to chemotherapy, during
the 12 weeks of chemotherapy, and 24 hours after chemotherapy. Patients are provided with all
meals and all food to be consumed and maintain a diary of the food consumed and appropriate
amounts. Patients meet with the study dietician within 3 weeks of enrollment and prior to, or
on the day of, their first course of chemotherapy on study and at the start of each
ARM II: Patients eat a normal diet and receive dietary advice which may include consultation
with a nutritionist. Patients maintain a diary of the food consumed and appropriate amounts.